Focused On-demand Library for SPRY domain-containing SOCS box protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q99619

UPID:

SPSB2_HUMAN

Alternative names:

Gene-rich cluster protein C9

Alternative UPACC:

Q99619; B7Z4W1; D3DUT0

Background:

The SPRY domain-containing SOCS box protein 2, also known as Gene-rich cluster protein C9, plays a crucial role in the ubiquitination and proteasomal degradation of target proteins. It is a key component of the SCF-like ECS E3 ubiquitin-protein ligase complex, which is essential for regulating protein levels within the cell. This protein specifically targets NOS2 for degradation, thereby negatively regulating nitric oxide production in activated macrophages, a critical process for limiting cellular toxicity.

Therapeutic significance:

Understanding the role of SPRY domain-containing SOCS box protein 2 could open doors to potential therapeutic strategies. Its involvement in regulating nitric oxide production and cellular toxicity highlights its potential as a target for developing treatments aimed at inflammatory conditions and diseases where nitric oxide plays a pivotal role.